IMCR
Immunocore Holdings PLC - ADR

515
Mkt Cap
$1.61B
Volume
287,352.00
52W High
$40.71
52W Low
$23.15
PE Ratio
-54.74
IMCR Fundamentals
Price
$33.26
Prev Close
$31.98
Open
$31.98
50D MA
$35.06
Beta
0.74
Avg. Volume
518,814.30
EPS (Annual)
-$1.02
P/B
4.09
Rev/Employee
$629,477.75
Loading...
Loading...
News
all
press releases
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen analysts that are currently covering...
MarketBeat·20h ago
News Placeholder
More News
News Placeholder
GSK Gets EU Approval for Expanded Use of Nucala in COPD
GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.
Zacks·4d ago
News Placeholder
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
Zacks·5d ago
News Placeholder
HC Wainwright Predicts Immunocore FY2030 Earnings
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Immunocore in a research note issued to investors on...
MarketBeat·5d ago
News Placeholder
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
Zacks·6d ago
News Placeholder
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study
Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.
Zacks·7d ago
News Placeholder
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU
ACAD expects a negative CHMP opinion on trofinetide marketing application for Rett syndrome, likely delaying a potential EU approval.
Zacks·7d ago
News Placeholder
Immunocore (NASDAQ:IMCR) Cut to "Hold" at Wall Street Zen
Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·10d ago
News Placeholder
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
Teva beats Q4 estimates driven by a Sanofi milestone and strong Austedo growth. The drugmaker also unveils its 2026 outlook.
Zacks·12d ago
News Placeholder
BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down
Bausch Health shares slide after late-stage RED-C trials for rifaximin SSD fail, derailing plans to expand Xifaxan's cirrhosis-related use.
Zacks·13d ago
<
1
2
...
>

Latest IMCR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.